Review

Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy

Yinghao Zhao^a Wei Yang^a Yuanyuan Huang^b Ranji Cui^a Xiangyan Li^c
Bingjin Li^a

^aJilin Provincial Key Laboratory on Molecular and Chemical Genetic, the Second Hospital of Jilin University, Changchun, ^bDepartment of pediatric, the First Hospital of Jilin University, Changchun, ^cJilin Provincial Key Laboratory of BioMacromolecules of Chinese Medicine, Jilin Ginseng Academy, Changchun University of Chinese Medicine, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, Jilin, China

Key Words

Ctla-4 • PD-1 • Antibody • ipilimumab • Tremelimumab

Abstract

Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) is a membrane glycoprotein expressed by activated effector T cells (Teffs) and participates in the repression of T cell proliferation, cell cycle progression and cytokine production. Currently, antibodies targeting CTLA-4, ipilimumab and tremelimumab are widely used as a therapeutic approach in a variety of human malignancies. However, their detailed mechanism remains unclear. Therefore, in this review, we focused specifically on recent findings concerning the role of CTLA-4 in immune response and also discussed clinical studies of targeting CTLA-4, alone or in combination with other therapies for the treatment of cancers. CTLA-4 blockade is used as a therapeutic approach for the treatment of cancer through competing with CD28-positive costimulation for binding to their shared B7 ligands or exhibiting direct inhibitory effect on signaling molecules in the cytoplasmic tail. At present, antibodies for targeting CTLA-4 or in combination with other therapies significantly reinforced the anti-tumor effect and improved the prognosis of malignant disease. In addition, severe adverse events of targeting CTLA-4 therapy could be a challenge for the development of this therapeutic strategy. This review may provide some new insights for clinical studies of targeting CTLA-4.

© 2018 The Author(s)
Published by S. Karger AG, Basel

Introduction

Immunotherapy is proved to be a promising therapeutic strategy against human malignancies. Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4, CD152) is a membrane glycoprotein expressed by activated effector T cells (Teffs) and participates in the repression of T cell proliferation, cell cycle progression and cytokine (IL-2, IFN- γ) production [1, 2].

Y. Zhao and W. Yang contributed equally to this work.

Xiangyan Li
and Bingjin Li

Jilin Provincial Key Laboratory on Molecular and Chemical Genetic
The Second Hospital of Jilin University, Changchun (China)
E-Mail xiangyan_li1981@163.com, libingjin@jlu.edu.cn

CTLA-4 exerts its inhibitory function mainly through multiple mechanisms including competition with CD28-positive costimulation for binding to their shared B7 ligands (CD80/CD86) on the antigen-presenting cells (APC), as well as direct inhibitory effects through the cytoplasmic tail which associates with signaling molecules [3]. Currently, targeting CTLA-4 by antibodies is used as a therapeutic approach in a variety of human malignancies, with the aim of blocking the inhibitory effects of CTLA-4 in T cells. Anti-CTLA-4 immunomodulating monoclonal antibodies (mAbs), ipilimumab and tremelimumab are used, either alone or in combination with chemotherapy, vaccine or other antibodies (anti-PD-1 [4, 5] or anti-OX40 [6, 7]), in the preclinical studies and clinical trials of malignancies, including melanoma [8-12], non-small cell lung cancer (NSCLC), breast cancer, prostate cancer [13], pancreatic cancer [14], hepatocellular carcinoma [15], mesothelioma [16].

In this review, we focused specifically on important findings concerning the role of CTLA-4 in immune response and also discussed clinical studies of targeting CTLA-4, alone or in combination with other therapies for the treatment of cancers.

Role of CTLA-4 in immune response

Structure and expression

CTLA-4 was first identified by differential screening of a murine cytolytic T cell cDNA library, which has similar structures as T cell surface molecule CD28 with similar functional properties [17-19]. Like CD28, CTLA-4 localizes on band q33-q34 of human chromosome 2, and on band C of mouse chromosome 1, which encodes a 223-amino-acid protein containing one variable-like domain flanked by two hydrophobic regions. The sequence homology between CD28 and CTLA-4 is about 20%, but they share a 27% (murine) to 30% (human) identity at the amino acid level [20, 21]. Human CTLA-4 contains a leader peptide and three domains, an extracellular V domain of 116 amino acids, a transmembrane region of 37 amino acids and a 34 amino acid cytoplasmic tail [22], which contains two tyrosine-based motifs at position Y₂₀₁ VKM and Y₂₁₈ FIP. Several intracellular proteins bind to the Y₂₀₁ VKM sequence including lipid kinase phosphatidylinositol 3-kinase (PI3K) [23], the phosphatases SH2 domain-containing protein tyrosine phosphatases (SHP-2), the serine threonine phosphatase PP2A [24, 25] and clathrin adaptor proteins activator protein 1 (AP-1) and AP-2 [26] (Fig. 1A).

Fig. 1. CTLA-4 structure and its gene polymorphisms in cancer. (A) The CTLA-4 protein consists of three domains (ligand binding region, transmembrane region and cytoplasmic tail) and a leader peptide, which corresponds to exon 2, exon 3, exon 4 and exon 1 in the CTLA-4 gene, respectively. The cytoplasmic tail of CTLA-4 contains two tyrosine-based motifs. The YVKM motif constitutes a binding site for the lipid PI3K, the phosphatases PP2A and SHP2 and the clathrin adaptor protein AP-1 and AP-2. (B) The gene polymorphisms with the CTLA-4 gene have been associated with susceptibility to different types of malignancies.

CTLA-4 protein was found to be primarily localized in intracellular vesicles and may cycle between intracellular stores and the cell surface. CTLA-4, a transmembrane glycoprotein, is induced largely on activated T cells, including memory and regulatory T cells [27] but expressed marginally on resting T cells [17, 28]. Specially, CTLA-4 is also expressed on different types of non-T cells, either normal [29, 30] or neoplastic cells [31]. In addition, Foxp3 amplified and stabilized CTLA-4 expression, which normally elaborated by conventional T cells upon TCR stimulation and capable of negative feedback regulation of T-cell activation [32]. Regulatory CD4⁺ T cells (Tr cells), the development of which is critically dependent on X-linked transcription factor Foxp3 (forkhead box P3), prevent self-destructive immune responses. Despite its important role, molecular and functional features conferred by Foxp3 to Tr precursor cells remain unknown. It has been suggested that Foxp3 expression is required for both survival of Tr precursors as well as their inability to produce interleukin (IL)-2 and independently proliferate after T-cell-receptor engagement, raising the possibility that such 'anergy' and Tr suppressive capacity are intimately linked. Here we show, by dissociating Foxp3-dependent features from those induced by the signals preceding and promoting its expression in mice, that the latter signals include several functional and transcriptional hallmarks of Tr cells. Although its function is required for Tr cell suppressor activity, Foxp3 to a large extent amplifies and fixes pre-established molecular features of Tr cells, including anergy and dependence on paracrine IL-2. Furthermore, Foxp3 solidifies Tr cell lineage stability through modification of cell surface and signaling molecules, resulting in adaptation to the signals required to induce and maintain Tr cells. This adaptation includes Foxp3-dependent repression of cyclic nucleotide phosphodiesterase 3B, affecting genes responsible for Tr cell homeostasis.

Several studies showed that persistent expression of CTLA-4 in the neoplastic cells from cancer patients contributes to the progression of both hematological [33-35] and solid tumors. Different CTLA-4 expression levels in different type of tumors might influence clinical outcome. For example, CTLA4 overexpression was detected in non-squamous type NSCLC and was related to patient age and histological differentiation, but not to the prognosis of clinical outcome [36]. High CTLA-4 mRNA levels were associated with good clinical outcome and longer period of time to treatment onset in B-cell chronic lymphocytic leukemia (CLL) [37]. However, the report showed that breast cancer patients with higher CTLA-4 mRNA levels had obvious axillary lymph node metastases and a higher clinical stage [38]. Patients with high tumor CTLA-4 expression in mesothelioma [39], nasopharyngeal carcinoma [40], melanoma [41] and NSCLC [36] had a poorer prognosis than those with low expression, which suggested CTLA-4 as a potential target for tumor immunotherapy.

CTLA-4 polymorphisms in cancer

More than 100 single nucleotide polymorphisms (SNPs) of CTLA-4 have been identified, for example, rs231775 G>A, rs3087243 G>A, rs4553808 A>G, rs5742909 C>T, rs733618 A>G, rs16840252 C>T polymorphisms, which play an important role in some autoimmune diseases and cancers [42-44]. Recent studies have suggested that SNPs [+49 (rs231775), CT60 (rs3087243), -1661 (rs4553808), and -318 (rs5742909)] in the promoter region of CTLA-4 gene may modulate the gene expression and are associated with susceptibility to different types of malignances, such as colorectal cancer [45, 46], breast cancer [43], hepatocellular carcinoma [47, 48], cervical cancer [48-50], melanoma [51], head and neck cancer [52], NSCLC [53, 54], renal cell carcinoma [55] and others [56] (Fig. 1B). However, some studies showed that lack of association between CTLA-4 polymorphisms and some types of cancer, including esophageal cancer in a Chinese population [57, 58] and breast cancer in a North Indian population [59]. It is required to confirm the findings in large-scale and multi-populations studies. Knowledge of the CTLA-4 polymorphism may provide useful information for donor selection and indications for individual application of immunotherapy in cancer.

Fig. 2. Model describing the mechanisms of CTLA-4 function in cancer. CTLA-4 shares the same B7 ligands as CD28, including B7-1 (CD80) and B7-2 (CD86) with negative effects on T cell activation. After T cell receptor (TCR) activation, CTLA-4 induces IDO (indoleamine-2, 3-dioxygenase), promotes Casitas-B-lineage lymphoma (Cbl)-b protein expression, suppresses the formation of zeta-associated protein of 70kDa (ZAP-70) and also induces inhibition of PI3K/Akt, cyclin D3-cdk4/6 and NF- κ B to negatively regulate T cell proliferation and activation by producing inhibitory signals to weaken the immune response against tumor.

Mechanisms of function

CTLA-4, a membrane receptor for cytotoxic T cells, shares the same B7 ligands as CD28, including B7-1 (CD80) and B7-2 (CD86) [60, 61], but it has negative effects on T cell activation [62, 63]. After T cell receptor (TCR) activation, CTLA-4 is up-regulated and binds B7 with a higher avidity than T lymphocyte receptor CD28, resulting in reduced T cell proliferation and lessened cytokine secretion [64-68]. In the early phase of tumorigenesis, CTLA-4 could decrease the T cell activation by producing inhibitory signals to weaken the immune response against tumor [69]. Additionally, CTLA-4 triggers reverse signaling through B7 to induce indoleamine-2, 3-dioxygenase (IDO), which leads to catabolization of the amino acid tryptophan and subsequently results in inhibition of T cell proliferation [70, 71]. Moreover, CTLA-4 was reported to promote the expression of Casitas-B-lineage lymphoma (Cbl)-b protein [72] or suppress the formation of zeta-associated protein of 70 kDa (ZAP 70) [73, 74] to negatively regulate T cell activation. Additionally, recent studies revealed that CTLA-4 induced inhibition of PI3K/Akt pathways, cyclin D3, cyclin-dependent kinases (cdk4/cdk6) and nuclear transcription factor (NF- κ B) [75-77] (Fig. 2). In spite of extensive researches on CTLA-4, mechanism of CTLA-4 interacting with its ligands or its downstream targets still needs to be further investigated.

Targeting CTLA-4 in cancer immunotherapy

CTLA-4 has a critical role in regulating the immune responses for tumors and considered as a potential target for tumor immunotherapy. A number of strategies for anti-CTLA-4 therapy relied on enhancing costimulation, including the use of irradiated tumor cells expressing GM-CSF to enhance crosspriming of T cells by APC, dendritic cells pulsed with peptides or RNA to afford immunization in conjunction with an APC [78]. Preclinical studies have confirmed that blockade of CTLA-4 potentiated therapeutic immunity against cancer [79-81]. At present, antibodies for targeting CTLA-4 (ipilimumab and tremelimumab)

Table 1. Clinical trials of CTLA-4 blocking antibodies or in combination with other therapies in human malignancies

Treatments	Phase	Tumor type	No. of patients	Dose	NCT number	Refs
Alone						
Ipilimumab	II	Advance melanoma	217	0.3, 3, 10mg/kg	NCT00289640	[83]
Ipilimumab	II	Advanced melanoma	155	10mg/kg	NCT00289627	[84]
Ipilimumab	III	Advanced melanoma	951	10mg/kg	NCT00636168	[85]
Ipilimumab	II	Metastatic renal cell carcinoma	61	3mg/kg followed by 1mg/kg or 3mg/kg		[86]
Ipilimumab	III	Castration resistant prostate cancer	799	10mg/kg	NCT00861614	[88]
Ipilimumab	I	Non-Hodgkin lymphoma	18	1.3mg/kg	NCT00089706	[87]
Tremelimumab	II	Malignant mesothelioma	29	15mg/kg	NCT01649024	[93]
Tremelimumab	II	Melanoma	251	15mg/kg	-	[90]
Tremelimumab	II	Refractory metastatic colorectal cancer	47	15mg/kg	-	[92]
Combination with other therapies						
Ipilimumab+ Carboplatin/Etoposide	II	Extensive-stage small cell lung cancer	42	10mg/kg	NCT01450761	[96]
Ipilimumab+ Carboplatin/Paclitaxel	I	Non-small cell lung cancer	15	3,10mg/kg	NCT01165216	[95]
Ipilimumab+ radiation therapy	I/II	Castration resistant prostate cancer	83	3,5,10mg/kg	NCT00323882	[101]
Ipilimumab+ radiation therapy	I	Solid tumors	35	3mg/kg	NCT02239900	[99]
Ipilimumab alone /+nivolumab (PD-1 antibody)	II	Advanced melanoma	142	3mg/kg	NCT01927419	[104]

or in combination with other therapies significantly reinforced the anti-tumor effect and improved the prognosis of malignant disease (Table 1).

Alone

Ipilimumab, the first anti-CTLA-4 human monoclonal antibody (IgG1) in humans, has been approved by FDA for the therapy of advanced melanoma patients in early 2011 [8, 82]. The randomized, double-blind and multicenter phase II trials revealed that ipilimumab elicited a dose-dependent effect on efficacy and safety measures in pretreated patients with advanced melanoma, lending support with encouraging long-term survival at a dose of 10 mg/kg. Moreover, a pharmacokinetic analysis performed demonstrated that ipilimumab had linear pharmacokinetics over the dose range 3 mg/kg to 10 mg/kg [83, 84]. The efficacy of ipilimumab was further validated by a randomized, double-blind, phase III trial after complete resection of high-risk stage III melanoma [85]. A phase II study of renal cell carcinoma demonstrated that ipilimumab induced cancer regression in some patients, even if they are not responded to other immunotherapies [86]. Moreover, blockade of CTLA-4 signaling using ipilimumab was well tolerated at the doses of 1 and 3 mg/kg, and had anti-tumor activity in patients with B-cell lymphoma [87]. However, a phase III trial showed no significant difference between ipilimumab group and the placebo group in terms of overall survival in patients with metastatic castration-resistant prostate cancer [88]. Although it did not show similar benefit as ipilimumab, clinical trials for tremelimumab demonstrated acceptable tolerability and clinically meaningful activity in patients with melanoma [89-91], refractory metastatic colorectal cancer [92], hepatocellular carcinoma [15] and malignant mesothelioma [93].

Combination with other therapies

Combination of CTLA-4 blockade with other therapies, such as chemotherapy, radiation therapy and other immunotherapy has been widely used for the treatment of a variety of cancers. Clinical studies revealed that the recommended dose of ipilimumab in phased combination with chemotherapies was identified as 10 mg/kg and had a better treatment benefit in combination with chemotherapeutic agents, such as carboplatin, etoposide and paclitaxel in patients with lung cancer [94-96] and advance melanoma [97, 98]. Moreover, combining radiotherapy and ipilimumab was feasible and well tolerated with limited toxicity for solid tumors [99]. The report showed that radiation with doses ranged from 45-61.2 Gy in patients with stage IIIA NSCLC after 3 cycles of neo-adjuvant chemotherapy including ipilimumab with the last two cycles was well tolerated with no observed grade ≥3 toxicity including NSCLC [100]. In patients with metastatic castration-resistant prostate cancer, the combination of ipilimumab with radiotherapy (8Gy/lesion, up to 3 lesions) showed synergistic antitumor activity with disease control and manageable adverse effects [101]. In addition, the efficacy of ipilimumab with other immunotherapies was evaluated in a number of clinical trials. Combination therapy with CTLA-4 and PD-1/PD-1L

potently could reverse immunosuppression and eradicate tumors via an intricate interplay between IFN- γ /IFN- γ R and IL-7/IL-7R pathways [75]. Nivolumab and pembrolizumab, specifically targeting PD-1, are widely studied antibodies for the treatment of cancers [102, 103]. For example, combination of nivolumab plus ipilimumab led to improved outcomes compared with ipilimumab alone in patients with advanced melanoma [104-107], metastatic osteosarcoma [108], colorectal cancer [109], recurrent glioblastoma [110] and renal cell carcinoma [111] with significantly longer overall survival and manageable safety. Recently, oncolytic viruses that selectively infect tumor tissues are a novel and promising technique for stimulating antitumor immunity. One study showed that measles virus(MV) vectors encoding antibodies against the T-cell inhibitory factors CTLA-4 and PD-1 improved therapeutic outcome in melanoma xenografts, suggesting rapid translation of combining immune checkpoint modulation with oncolytic viruses into clinical application [112]. The combination of ipilimumab and anti-receptor activator of NF- κ B (RANK) ligand (RANKL) denosumab in metastatic melanoma was recently reported [113]. A phase I clinical trial of ipilimumab in combination with bevacizumab (an antibody that inhibits angiogenesis) in patients with metastatic melanoma showed augmenting immune recognition in the tumor microenvironment through enhancing lymphocyte infiltration [114]. In addition, tremelimumab in combination with other therapies was also investigated and showed better clinical outcomes [93, 115].

Adverse events

Although treatments of targeting CTLA-4 have produced promising activities against malignant diseases, the drug-induced adverse events, termed “immune-related adverse events, (irAEs)” have been observed in some patients due to non-tumor-specific T cells activated by CTLA-4 blockade. IrAEs can have an impact on multiple organs and systems including skin, gastrointestinal tract, liver, endocrine system, eye, kidney, nervous system, pancreas and others, which have been reported in up to 72% of patients receiving ipilimumab [116-118]. Anti-CTLA-4-associated IrAEs are common and typically low grade and manageable, but can also be serious and life threatening. The skin and gastrointestinal tract are most frequently affected, while hepatic, endocrine, and neurologic events are less common [119]. Rash is generally the first irAEs to manifest and appears after the first or second dose of ipilimumab, which is different from those seen with other anticancer agents [120, 121]. Colitis and diarrhea are the most common gastrointestinal irAEs after the first few months of ipilimumab treatment, which can be very serious irAE, particularly in rare cases with the perforation of gastrointestinal tract. A phase III trial in patients with advanced melanoma demonstrated that the adverse events of ipilimumab were mild, with sporadic life threatening cases [122]. Approximately one-third of patients treated with ipilimumab had diarrhea, while colitis was observed in 7-22% of patients [123]. Recently, a study reported that anti-CTLA-4 antibodies might induce a severe and extensive form of inflammatory bowel disease, which suggests to be avoiding nonsteroidal anti-inflammatory drugs (NSAIDs) in patients treated with anti-CTLA-4 [124]. Hepatic irAEs are rare and may manifest as acute hepatitis pattern or as a biliary pattern, which can be reversed by corticosteroids [125]. In addition, autoimmune hypophysitis has been reported in up to 17% of patients with melanoma and renal cell carcinoma treated with anti-CTLA-4 therapy, which may related with enlarged pituitary gland and hormonal deficiencies [126]. The risk of irAEs was dependent on the dosage, with incidence of all-grade irAEs being evaluated to 61% for ipilimumab 3 mg/kg and 79% for ipilimumab 10mg/kg. The median time of onset of irAEs was about 10 weeks after the onset of treatment [118]. Severe adverse events of CTLA-4 blockade could have a limitation of the development of this therapeutic strategy, which could be a challenge for future researches that patients are able to benefit from ipilimumab therapy with adequate control of toxicities.

Conclusions and Perspectives

Currently, immunotherapy has been widely used in many forms of tumors, providing a new therapeutic strategy for cancer patients. Multiple studies demonstrated that persistent expression of CTLA-4 on tumors contributed to the progression of both hematological and solid tumors, which produced inhibitory signals to weaken the immune response. Therefore, blockade of CTLA-4 is becoming an attractive approach in enhancing immune efficacy against malignancies and improving the prognosis of tumor patients. In present, the antibodies targeting CTLA-4, ipilimumab and tremelimumab have been tested in many preclinical and clinical trials on a variety of tumors, which could provide new insights for understanding therapeutic effect of CTLA-4 blockade. However, the side effects of CTLA-4 antibodies were observed to be more common and more severe compared with PD-1 antibodies in one clinical trial. Therefore, multiple agents blocking CTLA-4 or in combination with other therapies are under development to reduce severe adverse events, which could be novel therapeutic strategy for cancer patients.

Disclosure Statement

The authors declare to have no conflict of interests.

Acknowledgements

This work was supported by Jilin Science and Technology Agency funding (20180414050GH and 20180519003JH).

References

- 1 Krummel MF, Allison JP: CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. *J Exp Med* 1996;183:2533-2540.
- 2 Brunner MC, Chambers CA, Chan FK, Hanke J, Winoto A, Allison JP: CTLA-4-Mediated inhibition of early events of T cell proliferation. *J Immunol* 1999;162:5813-5820.
- 3 Carreno BM, Bennett F, Chau TA, Ling V, Luxenberg D, Jussif J, Baroja ML, Madrenas J: CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression. *J Immunol* 2000;165:1352-1356.
- 4 Callahan MK, Postow MA, Wolchok JD: CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic. *Front Oncol* 2014;4:385.
- 5 Duraiswamy J, Freeman GJ, Coukos G: Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors--response. *Cancer Res* 2014;74:633-634; discussion 635.
- 6 Linch SN, Redmond WL: Combined OX40 ligation plus CTLA-4 blockade: More than the sum of its parts. *Oncoimmunology* 2014;3:e28245.
- 7 Redmond WL, Linch SN, Kasiewicz MJ: Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity. *Cancer Immunol Res* 2014;2:142-153.
- 8 Lipson EJ, Drake CG: Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. *Clin Cancer Res* 2011;17:6958-6962.
- 9 Robert C, Mateus C: [Anti-CTLA-4 monoclonal antibody: a major step in the treatment of metastatic melanoma]. *Med Sci (Paris)* 2011;27:850-858.
- 10 Wilgenhof S, Neyns B: Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient. *Ann Oncol* 2011;22:991-993.

- 11 Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, Levy CL, Rosenberg SA, Phan GQ: CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. *Clin Cancer Res* 2012;18:2039-2047.
- 12 Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ: Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med* 2010;363:711-723.
- 13 Youlin K, Li Z, Xiaodong W, Xiuheng L, Hengchen Z: Combination immunotherapy with 4-1BBL and CTLA-4 blockade for the treatment of prostate cancer. *Clin Dev Immunol* 2012;2012:439235.
- 14 Bajor DL, Vonderheide RH: Cracking the stone: combination vaccination and CTLA-4 blockade in pancreatic cancer. *J Immunother* 2013;36:362-364.
- 15 Sangro B, Gomez-Martin C, de la Mata M, Iñarrairaegui M, Garralda E, Barrera P, Riezu-Boj JI, Larrea E, Alfaro C, Sarobe P, Lasarte JJ, Pérez-Gracia JL, Melero I, Prieto J: A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. *J Hepatol* 2013;59:81-88.
- 16 Wu L, Yun Z, Tagawa T, Rey-McIntyre K, de Perrot M: CTLA-4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy in murine mesothelioma. *Mol Cancer Ther* 2012;11:1809-1819.
- 17 Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG, Golstein P: A new member of the immunoglobulin superfamily--CTLA-4. *Nature* 1987;328:267-270.
- 18 Harper K, Balzano C, Rouvier E, Mattéi MG, Luciani MF, Golstein P: CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location. *J Immunol* 1991;147:1037-1044.
- 19 Balzano C, Buonavista N, Rouvier E, Golstein P: CTLA-4 and CD28: similar proteins, neighbouring genes. *Int J Cancer Suppl* 1992;7:28-32.
- 20 Lafage-Pochitaloff M, Costello R, Couez D, Simonetti J, Mannoni P, Mawas C, Olive D: Human CD28 and CTLA-4 Ig superfamily genes are located on chromosome 2 at bands q33-q34. *Immunogenetics* 1990;31:198-201.
- 21 Howard TA, Rochelle JM, Seldin MF: Cd28 and Ctla-4, two related members of the Ig supergene family, are tightly linked on proximal mouse chromosome 1. *Immunogenetics* 1991;33:74-76.
- 22 Dariavach P, Mattéi MG, Golstein P, Lefranc MP: Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains. *Eur J Immunol* 1988;18:1901-1905.
- 23 Schneider H, Prasad KV, Shoelson SE, Rudd CE: CTLA-4 binding to the lipid kinase phosphatidylinositol 3-kinase in T cells. *J Exp Med* 1995;181:351-355.
- 24 Lee KM, Chuang E, Griffin M, Khattry R, Hong DK, Zhang W, Straus D, Samelson LE, Thompson CB, Bluestone JA: Molecular basis of T cell inactivation by CTLA-4. *Science* 1998;282:2263-2266.
- 25 Marengère LE, Waterhouse P, Duncan GS, Mittrücker HW, Feng GS, Mak TW: Regulation of T cell receptor signaling by tyrosine phosphatase SYP association with CTLA-4. *Science* 1996;272:1170-1173.
- 26 Schneider H, Martin M, Agarraberes FA, Yin L, Rapoport I, Kirchhausen T, Rudd CE: Cytolytic T lymphocyte-associated antigen-4 and the TCR zeta/CD3 complex, but not CD28, interact with clathrin adaptor complexes AP-1 and AP-2. *J Immunol* 1999;163:1868-1879.
- 27 Chambers CA, Kuhns MS, Allison JP: Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates primary and secondary peptide-specific CD4(+) T cell responses. *Proc Natl Acad Sci U S A* 1999;96:8603-8608.
- 28 Lindsten T, Lee KP, Harris ES, Petryniak B, Craighead N, Reynolds PJ, Lombard DB, Freeman GJ, Nadler LM, Gray GS: Characterization of CTLA-4 structure and expression on human T cells. *J Immunol* 1993;151:3489-3499.
- 29 Wang XB, Giscombe R, Yan Z, Heiden T, Xu D, Lefvert AK: Expression of CTLA-4 by human monocytes. *Scand J Immunol* 2002;55:53-60.
- 30 Laurent S, Carrega P, Saverino D, Piccioli P, Camoriano M, Morabito A, Dozin B, Fontana V, Simone R, Mortara L, Mingari MC, Ferlazzo G, Pistillo MP: CTLA-4 is expressed by human monocyte-derived dendritic cells and regulates their functions. *Hum Immunol* 2010;71:934-941.

- 31 Contardi E, Palmisano GL, Tazzari PL, Martelli AM, Falà F, Fabbi M, Kato T, Lucarelli E, Donati D, Polito L, Bolognesi A, Ricci F, Salvi S, Gargaglione V, Mantero S, Alberghini M, Ferrara GB, Pistillo MP: CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. *Int J Cancer* 2005;117:538-550.
- 32 Gavin MA, Rasmussen JP, Fontenot JD, Vasta V, Manganiello VC, Beavo JA, Rudensky AY: Foxp3-dependent programme of regulatory T-cell differentiation. *Nature* 2007;445:771-775.
- 33 Pistillo MP, Tazzari PL, Palmisano GL, Pierri I, Bolognesi A, Ferlito F, Capanni P, Polito L, Ratta M, Pileri S, Piccioli M, Basso G, Rissotto L, Conte R, Gobbi M, Stirpe F, Ferrara GB: CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cells. *Blood* 2003;101:202-209.
- 34 Kosmaczewska A, Ciszak L, Suwalska K, Wolowiec D, Frydecka I: CTLA-4 overexpression in CD19+/CD5+ cells correlates with the level of cell cycle regulators and disease progression in B-CLL patients. *Leukemia* 2005;19:301-304.
- 35 Joshi AD, Hegde GV, Dickinson JD, Mittal AK, Lynch JC, Eudy JD, Armitage JO, Bierman PJ, Bociek RG, Devetten MP, Vose JM, Joshi SS: ATM, CTLA4, MND4, and HEM1 in high versus low CD38 expressing B-cell chronic lymphocytic leukemia. *Clin Cancer Res* 2007;13:5295-5304.
- 36 Salvi S, Fontana V, Boccardo S, Merlo DF, Margallo E, Laurent S, Morabito A, Rijavec E, Dal Bello MG, Mora M, Ratto GB, Grossi F, Truini M, Pistillo MP: Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer. *Cancer Immunol Immunother* 2012;61:1463-1472.
- 37 Erfani N, Mehrabadi SM, Ghayumi MA, Haghshenas MR, Mojtahedi Z, Ghaderi A, Amani D: Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC). *Lung Cancer* 2012;77:306-311.
- 38 Mao H, Zhang L, Yang Y, Zuo W, Bi Y, Gao W, Deng B, Sun J, Shao Q, Qu X: New insights of CTLA-4 into its biological function in breast cancer. *Curr Cancer Drug Targets* 2010;10:728-736.
- 39 Roncella S, Laurent S, Fontana V, Ferro P, Franceschini MC, Salvi S, Varesano S, Boccardo S, Vigani A, Morabito A, Canessa PA, Giannoni U, Rosenberg I, Valentino A, Fedeli F, Merlo DF, Ceppi M, Riggio S, Romani M, Saverino D, Poggi A, Pistillo MP: CTLA-4 in mesothelioma patients: tissue expression, body fluid levels and possible relevance as a prognostic factor. *Cancer Immunol Immunother* 2016;65:909-917.
- 40 Huang PY, Guo SS, Zhang Y, Lu JB, Chen QY, Tang LQ, Zhang L, Liu LT, Zhang L, Mai HQ: Tumor CTLA-4 overexpression predicts poor survival in patients with nasopharyngeal carcinoma. *Oncotarget* 2016;7:13060-13068.
- 41 Shah KV, Chien AJ, Yee C, Moon RT: CTLA-4 is a direct target of Wnt/beta-catenin signaling and is expressed in human melanoma tumors. *J Invest Dermatol* 2008;128:2870-2879.
- 42 Yang M, Sun T, Zhou Y, Wang L, Liu L, Zhang X, Tang X, Zhou M, Kuang P, Tan W, Li H, Yuan Q, Yu D: The functional cytotoxic T lymphocyte-associated Protein 4 49G-to-A genetic variant and risk of pancreatic cancer. *Cancer* 2012;118:4681-4686.
- 43 Li D, Zhang Q, Xu F, Fu Z, Yuan W, Li D, Pang D: Association of CTLA-4 gene polymorphisms with sporadic breast cancer risk and clinical features in Han women of northeast China. *Mol Cell Biochem* 2012;364:283-290.
- 44 Karabon L, Pawlak-Adamska E, Tomkiewicz A, Jedynak A, Kielbinski M, Woszczyk D, Potoczek S, Jonkisz A, Kuliczowski K, Frydecka I: Variations in suppressor molecule ctla-4 gene are related to susceptibility to multiple myeloma in a polish population. *Pathol Oncol Res* 2012;18:219-226.
- 45 Qi P, Ruan CP, Wang H, Zhou FG, Xu XY, Gu X, Zhao YP, Dou TH, Gao CF: CTLA-4 +49A>G polymorphism is associated with the risk but not with the progression of colorectal cancer in Chinese. *Int J Colorectal Dis* 2010;25:39-45.
- 46 Wang L, Jing F, Su D, Zhang T, Yang B, Jiao S, Hu Y, Bai L: Association between CTLA-4 rs231775 polymorphism and risk of colorectal cancer: a meta analysis. *Int J Clin Exp Med* 2015;8:650-657.
- 47 Liu Z, Song Z, Sun J, Sun F, Li C, Sun J, Xu L: Association between CTLA-4 rs231775 polymorphism and hepatocellular carcinoma susceptibility. *Int J Clin Exp Pathol* 2015;8:15118-15122.
- 48 Hu L, Liu J, Chen X, Zhang Y, Liu L, Zhu J, Chen J, Shen H, Qiang F, Hu Z: CTLA-4 gene polymorphism +49 A/G contributes to genetic susceptibility to two infection-related cancers-hepatocellular carcinoma and cervical cancer. *Hum Immunol* 2010;71:888-891.

- 49 Gokhale P, Kerkar S, Tongaonkar H, Salvi V, Mania-Pramanik J: CTLA-4 gene polymorphism at position +49 A>G in exon 1: a risk factor for cervical cancer in Indian women. *Cancer Genet* 2013;206:154-161.
- 50 Lee YH, Song GG: A meta-analysis of the association between CTLA-4 +49 A/G, -318 C/T, and IL-1 polymorphisms and susceptibility to cervical cancer. *Neoplasma* 2014;61:481-490.
- 51 Queirolo P, Morabito A, Laurent S, Lastraioli S, Piccioli P, Ascierto PA, Gentilcore G, Serra M, Marasco A, Tornari E, Dozin B, Pistillo MP: Association of CTLA-4 polymorphisms with improved overall survival in melanoma patients treated with CTLA-4 blockade: a pilot study. *Cancer Invest* 2013;31:336-345.
- 52 Erfani N, Haghshenas MR, Hoseini MA, Hashemi SB, Khademi B, Ghaderi A: Strong association of CTLA-4 variation (CT60A/G) and CTLA-4 haplotypes with predisposition of Iranians to head and neck cancer. *Iran J Immunol* 2012;9:188-198.
- 53 Song B, Liu Y, Liu J, Song X, Wang Z, Wang M, Zhu Y, Han J: CTLA-4 +49A>G polymorphism is associated with advanced non-small cell lung cancer prognosis. *Respiration* 2011;82:439-444.
- 54 Ma Y, Liu X, Zhu J, Li W, Guo L, Han X, Song B, Cheng S, Jie L: Polymorphisms of co-inhibitory molecules (CTLA-4/PD-1/PD-L1) and the risk of non-small cell lung cancer in a Chinese population. *Int J Clin Exp Med* 2015;8:16585-16591.
- 55 Tupikowski K, Partyka A, Kolodziej A, Dembowski J, Debinski P, Halon A, Zdrojowy R, Frydecka I, Karabon L: CTLA-4 and CD28 genes' polymorphisms and renal cell carcinoma susceptibility in the Polish population--a prospective study. *Tissue Antigens* 2015;86:353-361.
- 56 Yan Q, Chen P, Lu A, Zhao P, Gu A: Association between CTLA-4 60G/A and -1661A/G polymorphisms and the risk of cancers: a meta-analysis. *PLoS One* 2013;8:e83710.
- 57 Tang W, Qiu H, Jiang H, Sun B, Wang L, Yin J, Gu H: Lack of association between cytotoxic T-lymphocyte antigen 4 (CTLA-4) -1722T/C (rs733618) polymorphism and cancer risk: from a case-control study to a meta-analysis. *PLoS One* 2014;9:e94039.
- 58 Liu C, Wang Y, Jiang H, Tang W, Chen S, Kang M, Dong C, Gu H: Association between Cytotoxic T-lymphocyte antigen 4 (CTLA-4) +49 G>A (rs231775) polymorphism and esophageal cancer: from a case-control study to a meta-analysis. *Int J Clin Exp Med* 2015;8:17664-17673.
- 59 Minhas S, Bhalla S, Shokeen Y, Jauhri M, Saxena R, Verma IC, Aggarwal S: Lack of any association of the CTLA-4 +49 G/A polymorphism with breast cancer risk in a North Indian population. *Asian Pac J Cancer Prev* 2014;15:2035-2038.
- 60 Boussiotis VA, Freeman GJ, Gribben JG, Daley J, Gray G, Nadler LM: Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation. *Proc Natl Acad Sci U S A* 1993;90:11059-11063.
- 61 Linsley PS, Greene JL, Brady W, Bajorath J, Ledbetter JA, Peach R: Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. *Immunity* 1994;1:793-801.
- 62 Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, Thompson CB, Bluestone JA: CTLA-4 can function as a negative regulator of T cell activation. *Immunity* 1994;1:405-413.
- 63 Krummel MF, Allison JP: CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. *J Exp Med* 1995;182:459-465.
- 64 Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA: CTLA-4 is a second receptor for the B cell activation antigen B7. *J Exp Med* 1991;174:561-569.
- 65 Schwartz RH: Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. *Cell* 1992;71:1065-1068.
- 66 Linsley PS, Greene JL, Tan P, Bradshaw J, Ledbetter JA, Anasetti C, Damle NK: Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. *J Exp Med* 1992;176:1595-1604.
- 67 Chen L, Ashe S, Brady WA, Hellström I, Hellström KE, Ledbetter JA, McGowan P, Linsley PS: Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. *Cell* 1992;71:1093-1102.
- 68 Azuma M, Ito D, Yagita H, Okumura K, Phillips JH, Lanier LL, Somoza C: B70 antigen is a second ligand for CTLA-4 and CD28. *Nature* 1993;366:76-79.
- 69 Egen JG, Kuhns MS, Allison JP: CTLA-4: new insights into its biological function and use in tumor immunotherapy. *Nat Immunol* 2002;3:611-618.
- 70 Boasso A, Herbeuval JP, Hardy AW, Winkler C, Shearer GM: Regulation of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA-synthetase by CTLA-4-Fc in human CD4+ T cells. *Blood* 2005;105:1574-1581.

- 71 Grohmann U, Orabona C, Fallarino F, Vacca C, Calcinaro F, Falorni A, Candeloro P, Belladonna ML, Bianchi R, Fioretti MC, Puccetti P: CTLA-4-Ig regulates tryptophan catabolism in vivo. *Nat Immunol* 2002;3:1097-1101.
- 72 Li D, Gál I, Vermes C, Alegre ML, Chong AS, Chen L, Shao Q, Adarichev V, Xu X, Koreny T, Mikecz K, Finnegan A, Glant TT, Zhang J: Cutting edge: Cbl-b: one of the key molecules tuning CD28- and CTLA-4-mediated T cell costimulation. *J Immunol* 2004;173:7135-7139.
- 73 Guntermann C, Alexander DR: CTLA-4 suppresses proximal TCR signaling in resting human CD4(+) T cells by inhibiting ZAP-70 Tyr(319) phosphorylation: a potential role for tyrosine phosphatases. *J Immunol* 2002;168:4420-4429.
- 74 Schneider H, Smith X, Liu H, Bismuth G, Rudd CE: CTLA-4 disrupts ZAP70 microcluster formation with reduced T cell/APC dwell times and calcium mobilization. *Eur J Immunol* 2008;38:40-47.
- 75 Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, Linsley PS, Thompson CB, Riley JL: CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. *Mol Cell Biol* 2005;25:9543-9553.
- 76 Kubsch S, Graulich E, Knop J, Steinbrink K: Suppressor activity of anergic T cells induced by IL-10-treated human dendritic cells: association with IL-2- and CTLA-4-dependent G1 arrest of the cell cycle regulated by p27Kip1. *Eur J Immunol* 2003;33:1988-1997.
- 77 Olsson C, Riesbeck K, Dohlsten M, Michaëlsson E, Riebeck K: CTLA-4 ligation suppresses CD28-induced NF-kappaB and AP-1 activity in mouse T cell blasts. *J Biol Chem* 1999;274:14400-14405.
- 78 Wolchok JD, Saenger Y: The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. *Oncologist* 2008;13 Suppl 4:2-9.
- 79 Leach DR, Krummel MF, Allison JP: Enhancement of antitumor immunity by CTLA-4 blockade. *Science* 1996;271:1734-1736.
- 80 Mokyr MB, Kalinichenko T, Gorelik L, Bluestone JA: Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice. *Cancer Res* 1998;58:5301-5304.
- 81 Sabel MS, Hess SD, Egilmez NK, Conway TF, Chen FA, Bankert RB: CTLA-4 blockade augments human T lymphocyte-mediated suppression of lung tumor xenografts in SCID mice. *Cancer Immunol Immunother* 2005;54:944-952.
- 82 Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH, Gascon P, Lotem M, Harmanakaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. *N Engl J Med* 2011;364:2517-2526.
- 83 Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, Waterfield W, Schadendorf D, Smylie M, Guthrie T, Grob JJ, Chesney J, Chin K, Chen K, Hoos A, O'Day SJ, Lebbé C: Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. *Lancet Oncol* 2010;11:155-164.
- 84 O'Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, Queirolo P, Lundgren L, Mikhailov S, Roman L, Verschraegen C, Humphrey R, Ibrahim R, de Pril V, Hoos A, Wolchok JD: Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. *Ann Oncol* 2010;21:1712-1717.
- 85 Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbé C, Ferraresi V, Smylie M, Weber JS, Maio M, Konto C, Hoos A, de Pril V, Gurunath RK, de Schaetzen G, Suci S, Testori A: Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. *Lancet Oncol* 2015;16:522-530.
- 86 Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL, Suri KB, Levy C, Allen T, Mavroukakis S, Lowy I, White DE, Rosenberg SA: Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. *J Immunother* 2007;30:825-830.
- 87 Ansell SM, Hurvitz SA, Koenig PA, LaPlant BR, Kabat BF, Fernando D, Habermann TM, Inwards DJ, Verma M, Yamada R, Erlichman C, Lowy I, Timmerman JM: Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. *Clin Cancer Res* 2009;15:6446-6453.

- 88 Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Maio M, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengeløv L, Hansen S, Logothetis C, Beer TM, McHenry MB, Gagnier P, Liu D, Gerritsen WR: Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. *Lancet Oncol* 2014;15:700-712.
- 89 Camacho LH, Antonia S, Sosman J, Kirkwood JM, Gajewski TF, Redman B, Pavlov D, Bulanhagui C, Bozon VA, Gomez-Navarro J, Ribas A: Phase I/II trial of tremelimumab in patients with metastatic melanoma. *J Clin Oncol* 2009;27:1075-1081.
- 90 Kirkwood JM, Lorigan P, Hersey P, Hauschild A, Robert C, McDermott D, Marshall MA, Gomez-Navarro J, Liang JQ, Bulanhagui CA: Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. *Clin Cancer Res* 2010;16:1042-1048.
- 91 Joshua AM, Monzon JG, Mihalcioiu C, Hogg D, Smylie M, Cheng T: A phase 2 study of tremelimumab in patients with advanced uveal melanoma. *Melanoma Res* 2015;25:342-347.
- 92 Chung KY, Gore I, Fong L, Venook A, Beck SB, Dorazio P, Criscitiello PJ, Healey DI, Huang B, Gomez-Navarro J, Saltz LB: Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. *J Clin Oncol* 2010;28:3485-3490.
- 93 Calabrò L, Morra A, Fonsatti E, Cutaia O, Amato G, Giannarelli D, Di GAM, Danielli R, Altomonte M, Mutti L, Maio M: Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. *Lancet Oncol* 2013;14:1104-1111.
- 94 Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Neal J, Lu H, Cuillerot JM, Reck M: Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. *J Clin Oncol* 2012;30:2046-2054.
- 95 Horinouchi H, Yamamoto N, Fujiwara Y, Sekine I, Nokihara H, Kubota K, Kanda S, Yagishita S, Wakui H, Kitazono S, Mizugaki H, Tokudome T, Tamura T: Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer. *Invest New Drugs* 2015;33:881-889.
- 96 Arriola E, Wheeler M, Galea I, Cross N, Maishman T, Hamid D, Stanton L, Cave J, Geldart T, Mulatero C, Potter V, Danson S, Woll PJ, Griffiths R, Nolan L, Ottensmeier C: Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC. *J Thorac Oncol* 2016;11:1511-1521.
- 97 Hersh EM, O'Day SJ, Powderly J, Khan KD, Pavlick AC, Cranmer LD, Samlowski WE, Nichol GM, Yellin MJ, Weber JS: A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. *Invest New Drugs* 2011;29:489-498.
- 98 Weber J, Hamid O, Amin A, O'Day S, Masson E, Goldberg SM, Williams D, Parker SM, Chasalow SD, Alaparthi S, Wolchok JD: Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma. *Cancer Immun* 2013;13:7.
- 99 Tang C, Welsh JW, de Groot P, Massarelli E, Chang JY, Hess KR, Basu S, Curran MA, Cabanillas ME, Subbiah V, Fu S, Tsimberidou AM, Karp D, Gomez DR, Diab A, Komaki R, Heymach JV, Sharma P, Naing A, Hong DS: Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. *Clin Cancer Res* 2017;23:1388-1396.
- 100 Boyer MJ, Gu L, Wang X, Kelsey CR, Yoo DS, Onaitis MW, Dunphy FR, Crawford J, Ready NE, Salama JK: Toxicity of definitive and post-operative radiation following ipilimumab in non-small cell lung cancer. *Lung Cancer* 2016;98:76-78.
- 101 Slovin SF, Higano CS, Hamid O, Tejwani S, Harzstark A, Alumkal JJ, Scher HI, Chin K, Gagnier P, McHenry MB, Beer TM: Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. *Ann Oncol* 2013;24:1813-1821.
- 102 Tie Y, Ma X, Zhu C, Mao Y, Shen K, Wei X, Chen Y, Zheng H: Safety and efficacy of nivolumab in the treatment of cancers: A meta-analysis of 27 prospective clinical trials. *Int J Cancer* 2017;140:948-958.
- 103 Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Ellassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumei PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A: Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. *N Engl J Med* 2013;369:134-144.

- 104 Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor DR, Salama AK, Taylor MH, Ott PA, Horak C, Gagnier P, Jiang J, Wolchok JD, Postow MA: Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. *Lancet Oncol* 2016;17:1558-1568.
- 105 Tsui E, Madu A, Belinsky I, Yannuzzi LA, Freund KB, Modi YS: Combination Ipilimumab and Nivolumab for Metastatic Melanoma Associated With Ciliochoroidal Effusion and Exudative Retinal Detachment. *JAMA Ophthalmol* 2017;135:1455-1457.
- 106 Callahan MK, Kluger H, Postow MA, Segal NH, Lesokhin A, Atkins MB, Kirkwood JM, Krishnan S, Bhole R, Horak C, Wolchok JD, Sznol M: Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study. *J Clin Oncol* 2018;36:391-398.
- 107 Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, Smylie M, Dummer R, Hill A, Hogg D, Haanen J, Carlino MS, Bechter O, Maio M, Marquez-Rodas I, Guidoboni M, McArthur G, Lebbé C, Ascierto PA, Long GV, Cebon J, Sosman J, Postow MA, Callahan MK, Walker D, Rollin L, Bhole R, Hodi FS, Larkin J: Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. *N Engl J Med* 2017;377:1345-1356.
- 108 Lussier DM, Johnson JL, Hingorani P, Blattman JN: Combination immunotherapy with α -CTLA-4 and α -PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma. *J Immunother Cancer* 2015;3:21.
- 109 Overman MJ, Lonardi S, KYM W, Lenz HJ, Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill A, Sawyer MB, Hendlish A, Neyns B, Svrcek M, Moss RA, Ledezine JM, Cao ZA, Kamble S, Kopetz S, André T: Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. *J Clin Oncol* 2018;36:773-779.
- 110 Omuro A, Vlahovic G, Lim M, Sahebjam S, Baehring J, Cloughesy T, Voloschin A, Ramkissoon SH, Ligon KL, Latek R, Zwirter S, Strauss L, Paliwal P, Harbison CT, Reardon DA, Sampson JH: Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase 1 cohorts of CheckMate 143. *Neuro Oncol* 2017.
- 111 Hammers HJ, Plimack ER, Infante JR, Rini BI, McDermott DF, Lewis LD, Voss MH, Sharma P, Pal SK, ARA R, Kollmannsberger C, DYH H, Sprattlin J, McHenry MB, Amin A: Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study. *J Clin Oncol* 2017;35:3851-3858.
- 112 Engeland CE, Grossardt C, Veinalde R, Bossow S, Lutz D, Kaufmann JK, Shevchenko I, Umansky V, Nettelbeck DM, Weichert W, Jäger D, von KC, Ungerechts G: CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy. *Mol Ther* 2014;22:1949-1959.
- 113 Smyth MJ, Yagita H, McArthur GA: Combination Anti-CTLA-4 and Anti-RANKL in Metastatic Melanoma. *J Clin Oncol* 2016;34:e104-106.
- 114 Wu X, Giobbie-Hurder A, Liao X, Lawrence D, McDermott D, Zhou J, Rodig S, Hodi FS: VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma. *Cancer Immunol Res* 2016;4:858-868.
- 115 Duffy AG, Ulahannan SV, Makorova-Rusher O, Rahma O, Wedemeyer H, Pratt D, Davis JL, Hughes MS, Heller T, ElGindi M, Uppala A, Korangy F, Kleiner DE, Figg WD, Venzon D, Steinberg SM, Venkatesan AM, Krishnasamy V, Abi-Jaoudeh N, Levy E, Wood BJ, Gretten TF: Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. *J Hepatol* 2017;66:545-551.
- 116 Voskens CJ, Goldinger SM, Loquai C, Robert C, Kaehler KC, Berking C, Bergmann T, Bockmeyer CL, Eigentler T, Fluck M, Garbe C, Gutzmer R, Grabbe S, Hauschild A, Hein R, Hundorfean G, Justich A, Keller U, Klein C, Mateus C, Mohr P, Paetzold S, Satzger I, Schadendorf D, Schlaeppli M, Schuler G, Schuler-Thurner B, Trefzer U, Ulrich J, Vaubel J, von MR, Weder P, Wilhelm T, Göppner D, Dummer R, Heinzerling LM: The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. *PLoS One* 2013;8:e53745.
- 117 Weber JS, Kähler KC, Hauschild A: Management of immune-related adverse events and kinetics of response with ipilimumab. *J Clin Oncol* 2012;30:2691-2697.
- 118 Bertrand A, Kostine M, Barnette T, Truchetet ME, Schaefferbeke T: Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. *BMC Med* 2015;13:211.

- 119 Tarhini A: Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management. *Scientifica (Cairo)* 2013;2013:857519.
- 120 Fecher LA, Agarwala SS, Hodi FS, Weber JS: Ipilimumab and its toxicities: a multidisciplinary approach. *Oncologist* 2013;18:733-743.
- 121 Lacouture ME, Wolchok JD, Yosipovitch G, Kähler KC, Busam KJ, Hauschild A: Ipilimumab in patients with cancer and the management of dermatologic adverse events. *J Am Acad Dermatol* 2014;71:161-169.
- 122 Weber JS, Dummer R, de Pril V, Lebbé C, Hodi FS: Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. *Cancer* 2013;119:1675-1682.
- 123 Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, Kammula US, Topalian SL, Sherry RM, Kleiner D, Quezado M, Lowy I, Yellin M, Rosenberg SA, Yang JC: Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. *J Clin Oncol* 2006;24:2283-2289.
- 124 Marthey L, Mateus C, Mussini C, Nachury M, Nancey S, Grange F, Zallot C, Peyrin-Biroulet L, Rahier JF, de Beauregard M B, Mortier L, Coutzac C, Soularue E, Lanoy E, Kapel N, Planchard D, Chaput N, Robert C, Carbonnel F: Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease. *J Crohns Colitis* 2016;10:395-401.
- 125 Kim KW, Ramaiya NH, Krajewski KM, Jagannathan JP, Tirumani SH, Srivastava A, Ibrahim N: Ipilimumab associated hepatitis: imaging and clinicopathologic findings. *Invest New Drugs* 2013;31:1071-1077.
- 126 Dillard T, Yedinak CG, Alumkal J, Fleseriu M: Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. *Pituitary* 2010;13:29-38.